|
| 产地 | 中国 |
| 品牌 | Chemstan |
| 货号 | CSD00004 |
| 保存条件 | store at -80℃ |
| 用途 | 仅用于科研用途 |
| 应用范围 | |
| 抗原来源 | CHO cells |
| CAS编号 | 216974-75-3 |
| 保质期 | 一年 |
| 抗体名 | Bevacizumab ( 贝伐珠单抗 ) |
| 是否单克隆 | |
| 克隆性 | |
| 靶点 | VEGFA[Homo sapiens] |
| 适应物种 | |
| 形态 | |
| 宿主 | |
| 标记物 | |
| 包装规格 | 100μg |
| 纯度 | % |
| 亚型 | |
| 标识物 | |
| 浓度 | 95% |
| 免疫原 | |
| 是否进口 | 否 |
货号（Catalog No.）
CSD00004
通用名INN
Bevacizumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab, a humanized monoclonal antibody,specifically binds to all VEGF-A isoforms with high affinity.
别名(Alternative names)
12-IgG1,F(ab)-12 IgG1,Fab-12 IgG1,rhuMAb-VEGF
靶点;物种(Specificity target name;species)
VEGFA[Homo sapiens]
活性研究（体外/体内研究）(Activity in vitro)
Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2. Experimental analysis shows that the EC50 of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50 value of 0.047±0.0081 μg/mL.
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-kappa
化学信息
分子量(MV)
149000.00 Da
CAS
216974-75-3
存储条件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .
